---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-071491"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2024-08-21T23:59:59+00:00"
generated_at: "2026-05-31T08:19:41.318762+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Silexion closes SPAC merger with Moringa; begins trading on Nasdaq under SLXN

## Summary
- 9,768,396 New Silexion ordinary shares outstanding post-closing; 87,722 Moringa public shares survived redemptions.
- Redemption of 427,297 Moringa shares at ~$11.575 for total ~$4.95M from trust account.
- Raised $2M via PIPE at $10/share from Greenstar LP; secured up to $15M ELOC with White Lion Capital.
- Issued $1.25M convertible note to EarlyBird (6% interest, due 2025) plus $3.433M sponsor promissory note.
- Adopted 2024 Equity Incentive Plan; lock-ups for insiders with 6-month cliff and potential $12 price trigger.

## SEC filing metadata
- accession: 0001213900-24-071491
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2024-08-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 2.01, 5.06, 3.02, 5.03, 2.03, 3.03, 5.01, 5.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/0001213900-24-071491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea0211976-8k_silexion.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-071491
- JSON: https://secwatch.observer/filing/0001213900-24-071491.json
- Plain text: https://secwatch.observer/filing/0001213900-24-071491.txt

## Key facts
- M&A Transactions
  Silexion Therapeutics Corp underwent a change of control involving Moringa Acquisition Corp, Silexion Therapeutics Ltd. (closed 2024-08-15).
  - Action: change of control
  - Counterparty: Moringa Acquisition Corp, Silexion Therapeutics Ltd.
  - Closing: 2024-08-15
  source text: On August 15, 2024 (the "Closing Date"), Silexion Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (the "registrant") consummated the previously announced transactions pursuant to that certain Amended and Restated Business Combination Agreement, dated as of April 3, 2024 (as amended, the "Business Combination Agreement"), by and among the registrant, Moringa Acquisition Corp ("Moringa"), August M.S. Ltd., an Israeli company and a wholly-owned subsidiary of the registrant ("Merger Sub 1"), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly-owned subsidiary of the registrant ("Merger Sub 2"), and Silexion Therapeutics Ltd., an Israeli company ("Silexion").
  evidence_url: https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/0001213900-24-071491-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.